Northwest Bio Collaborating With Leading UK Cancer Institutions For DCVax®-Direct Trial

Northwest Bio Collaborating With Leading UK Cancer Institutions For DCVax®-Direct Trial PR Newswire BETHESDA, Maryland, Nov. 6 , 2012 -Phase I/II Trial for Colon Cancer – Second Leading Cause of Cancer Deaths BETHESDA, Maryland, Nov. 6 , 2012 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio) a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that it has initiated a collaboration with Sarah Cannon Research UK and the Leaders in Oncology Care (LOC) on a Phase I/II trial with DCVax®-Direct for metastatic colon cancer. Sarah Cannon Research UK is the UK arm of the Sarah Cannon Research Institute, which specializes in cancer drug development and has a network of more than 700 physicians in the US and UK. http://photos.prnewswire.com/prnh/20110329/SF73084LOGO Colon cancer is the second leading cause of cancer deaths (after lung cancer), exceeding even deaths from breast cancer or prostate cancers. DCVax®-Direct offers an important potential new treatment option for colon cancer patients whose cancer has spread and is no longer operable. DCVax®-Direct is specifically designed to treat inoperable cancers in various tissues through direct injection into the tumors. It can be injected into any number of tumors, and virtually any location in the body (with imaging guidance for interior tissues). As previously reported, the Company has received FDA approval for a 36-patient Phase I/II trial in any solid tumor cancers.